Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 97 of the 100 references it cites were found in a registry or an index.

PPAR : a dagger in the heart of the metabolic syndrome

Open access
Barish, G. D. · 2006 · Journal of Clinical Investigation

Abstract

Obesity is a growing threat to global health by virtue of its association with insulin resistance, glucose intolerance, hypertension, and dyslipidemia, collectively known as the metabolic syndrome or syndrome X. The nuclear receptors PPARalpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively, and drugs that modulate these receptors are currently in clinical use. More recent work on the less-described PPAR isotype PPARdelta has uncovered a dual benefit for both hypertriglyceridemia and insulin resistance, highlighting the broad potential of PPARdelta in the treatment of metabolic disease. PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. Its combined activities in these and other tissues make it a multifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance, improve insulin sensitivity, and ameliorate atherosclerosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci27955

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Research works printed but not linked: 1

  1. [77]Lee, C.H., et al. 2006. PPAR delta is a potent insulin sensitizer. Proc. Natl. Acad. Sci. U. S. A. In press.

Cited by

See all 738

Metadata

Authors
Barish, G. D.
Affiliations
Salk Institute for Biological Studies (US)
Corresponding author
Barish, G. D.
Venue
Journal of Clinical Investigation
Published
2006-03-01
Volume
116
Issue
3
Pages
590-597
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1987601141
Cited by
641
References
100
Citations by year
2026: 12 · 2025: 12 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 23 · 2019: 15 · 2018: 24 · 2017: 26 · 2016: 28 · 2015: 29 · 2014: 31 · 2013: 39 · 2012: 46
FWCI
5.86
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Howard Hughes Medical Institute
  • March of Dimes Foundation
  • Larry L. Hillblom Foundation
  • National Institutes of Health (U19DK62434)
  • University of California, San Diego
  • National Heart, Lung, and Blood Institute (P50HL56989, P50HL056989)
  • National Institute of Diabetes and Digestive and Kidney Diseases (U19 DK-62434, U19DK062434, F32DK071478)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
PPARδ, PPARα, PPARγ, metabolic syndrome, insulin resistance, hypertriglyceridemia, obesity, fatty acid degradation, adipose tissue, skeletal muscle, macrophage inflammation, atherosclerosis, nuclear receptors, weight gain, physical endurance
MeSH terms
Animals, Humans, Myocardium, Muscle, Skeletal, Metabolic Syndrome, PPAR delta, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PPAR : a dagger in the heart of the metabolic syndrome. https://app.cochat.ai/papers/10.1172/jci27955
The paper
Barish, G. D. (2006). PPAR : a dagger in the heart of the metabolic syndrome. Journal of Clinical Investigation. https://doi.org/10.1172/jci27955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.